US-Wide VC Spending Falls 3 Percent in Q3; Life Science Clusters Record Big Declines | GenomeWeb
Private-equity capital destined for biotechnology and pharmaceutical companies nationwide contracted 2.7 percent in the third quarter due in part to a dip in seed and series A venture capital financing, and despite a steady supply of VC support at later stages and a slight uptick in overall seed-round money, according to Ernst & Young and Dow Jones VentureOne.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.